Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. Daver NG, Dail M, Garcia JS, Jonas BA, et al. Blood 2023;141:1265-1276.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Daver NG, Dail M, Garcia JS, Jonas BA, et al. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. Blood 2023;141:1265-1276.
PMID: 36265087